---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-006499"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2026-10-07T20:45:15+00:00"
generated_at: "2026-10-12T15:48:42.669155+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Profound Medical prelim Q3 2026 revenue $9.8-10.0M, up ~85-89% YoY and 45-47% above consensus

## Summary
- Preliminary Q3 2026 total revenue expected at $9.8M-$10.0M, versus Bloomberg mean analyst consensus of $6.78M as of Oct 7, 2026.
- Revenue up approximately 85% to 89% YoY from $5.3M in Q3 2025, and up 292% to 300% sequentially from $2.5M in Q2 2026.
- Q3 2026 gross margin expected to again exceed 70%, which the company attributes to commercial operations and scale.
- CEO Arun Menawat cites increased commercial activity across the installed base and new customer accounts; figures are preliminary and unaudited.
- Full Q3 2026 results due after market close Thursday, November 5, 2026, with a conference call at 4:30 p.m. ET.

## SEC filing metadata
- accession: 0001171843-26-006499
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2026-10-07T20:45:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184326006499/0001171843-26-006499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184326006499/f8k_100726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-006499
- JSON: https://secwatch.observer/filing/0001171843-26-006499.json
- Plain text: https://secwatch.observer/filing/0001171843-26-006499.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.